So-Young International Q2 Earnings Call Highlights
So-Young International reported Q2 earnings, highlighting 52% same-store sales growth and improved unit-level profitability. Aesthetic treatment revenue grew, while other segments declined. Gross margin increased to 28.1%. The company expects Q3 aesthetic revenue of RMB352M-RMB362M, up 91.7%-97.2% YoY. Management plans to focus on clinic growth and reduce investment in loss-making businesses.
How this was made
The 30-second read
Why it matters
Traders can update SY’s revenue trajectory and margin assumptions based on the provided next-quarter range and management’s stated drivers for further gross-margin improvement in Q3 and Q4.
Market read
Fresh guidance and operational KPIs (same-store sales, gross margin, profitability centers, and capacity utilization benchmark) create a near-term catalyst for earnings-model revisions.
What to watch
Cost of revenue rose 53% and operating expenses rose 10.4%, so margin expansion may depend on execution of supply-chain and center maturing rather than purely demand.
Background
The piece summarizes highlights from So-Young International’s Q2 earnings call, covering unit economics, segment trends, product/AI initiatives, and next-quarter guidance.
Ticker impact
So-Young guided next-quarter aesthetic treatment services revenue to RMB352 million to RMB362 million, implying 91.7% to 97.2% YoY growth.
Moderately positive bias for SY as traders price in strong YoY growth and continued gross-margin improvement into Q3-Q4.
The article includes explicit next-quarter revenue guidance plus operational KPIs (gross margin +3.8pp to 28.1%, same-store sales +52%) and a stated plan for further margin gains, which are actionable for earnings-model updates.
Market effects
Reinforces a read-through that China medical aesthetics operators can scale clinic networks while improving unit economics, supporting sector sentiment.
Could modestly influence sentiment toward China consumer health and platform-enabled healthcare services equities.
Limited direct global spillover, but may affect international investors' risk appetite for China healthcare growth stories.
Counterpoint
Despite strong aesthetic segment metrics, declines in information/reservation services and other services suggest diversification risk and potential volatility in non-core revenue.
Key entities
- public_companySo-Young International
NASDAQ-listed medical aesthetics platform and clinic network operator in China.
- productMiracle Collagen
Jointly developed product launched in late April, reported to have sold more than 66,000 units to date.
- productWeaveCol
Product launched in June as part of the company’s co-creation model.
